Comparative Pharmacology
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 10 11.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 10 11.
ENDOMETRIN vs NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
Combination oral contraceptive; ethinyl estradiol suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, inhibiting ovulation; norethindrone alters cervical mucus, endometrial lining, and sperm penetration.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-10; norethindrone 1 mg/ethinyl estradiol 35 mcg for days 11-21) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Norethindrone: terminal half-life ~7-8 hours. Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours). Clinical context: Steady-state achieved within ~5-10 days; dosing interval based on maintaining contraceptive efficacy.
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Norethindrone and ethinyl estradiol are primarily eliminated via renal excretion. Norethindrone is excreted as glucuronide and sulfate conjugates, with ~50% renal and ~20-30% fecal. Ethinyl estradiol is extensively metabolized; ~40% renal and ~60% fecal as conjugates.
Category C
Category D/X
Progestin
Progestin